tirofiban has been researched along with ST Elevation Myocardial Infarction in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 16 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, YJ; Liu, WG; Ma, Z; Ning, B; Wu, D | 1 |
| Dong, H; Hu, X; Lin, Y; Wang, W; Ye, J; Yu, B; Zhou, L; Zhou, Y | 1 |
| Chilbert, MR; Denny, O; Mills, K; Woodruff, AE | 1 |
| Li, R; Tang, X; Zhang, T | 1 |
| Argentiero, D; D'Andrea, P; Iacovelli, F; Savonitto, S | 1 |
| Brockmeyer, M; Dannenberg, L; Heinen, Y; Jung, C; Karathanos, A; Kelm, M; Lin, Y; Parco, C; Perings, S; Polzin, A; Schulze, V; Wolff, G; Zeymer, U | 1 |
| Amos, D; Brieger, D; Elder, A; Lowe, HC; McGhie, D | 1 |
| Al-Kaffas, S; Basuoni, A; El-Naggar, W; Mahdy, M | 1 |
| Duan, W; Hou, Y; Jiao, Y; Li, S; Ma, Q; Ma, Y; Sun, Z; Wang, X; Wen, Z; Wu, J; Yu, T | 1 |
| Avvedimento, M; Billinger, M; Campo, G; Cirillo, P; Esposito, G; Gargiulo, G; Gragnano, F; Heg, D; Hunziker, L; Manavifar, N; Minuz, P; Nagler, M; Piccolo, R; Tebaldi, M; Valgimigli, M; Wahl, A; Windecker, S | 1 |
| Feng, M; Wang, H | 1 |
| Dambrink, JHE; Fabris, E; Giannitsis, E; Gosselink, AM; Hamm, C; Hermanides, RS; Koopmans, PC; Ottervanger, JP; Sinagra, G; Ten Berg, JM; van 't Hof, AWJ | 1 |
| Chen, KC; Chiu, YW; Chuang, W; Hsu, JC; Ke, SR; Li, AH; Liao, PC; Liu, YH; Wu, YW; Yeh, YT | 1 |
| Jiménez Melo, O; Linares-Vicente, JA; Lukic, A; Martínez Labuena, A; Meseguer González, D; Morlanes Gracia, P; Revilla-Martí, P; Ruiz Arroyo, JR; Simó Sánchez, B | 1 |
| Angiolillo, DJ; Bhatt, DL; Stone, GW | 1 |
| Gargiulo, G; Nagler, M; Valgimigli, M | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Fabris, E; Giannitsis, E; Hamm, C; Kennedy, MW; Kilic, S; Kolkman, E; Ottervanger, JP; Schellings, DAAM; Ten Berg, JM; van Houwelingen, KG; Van't Hof, AWJ | 1 |
| Fracassi, F; Jang, IK; Lee, H; Sugiyama, T; Xing, L; Yamamoto, E; Yu, B | 1 |
| Gao, D; Hu, S; Li, H; Li, M; Wang, H; Zhang, H; Zhu, J | 1 |
| Davakhar, S; Hiremath, S; Krishna, K; Lakade, S | 1 |
| Li, J; Li, W; Wu, W; Xie, Q; Zhang, W; Zhang, Y; Zhang, Z | 1 |
| Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Levkau, B; Mourikis, P; Naguib, D; Pöhl, M; Polzin, A; Schulze, V; Wolff, G; Zako, S; Zeus, T | 1 |
| Akdeniz, E; Demir, K; Guvenc, RC; Guvenc, TS; Guzelburc, O; Kalenderoglu, K; Oz, A; Safak, A; Tekkesin, AI; Velibey, Y; Yildiz, U | 1 |
| Fabris, E; Giannitsis, E; Hamm, C; Hermanides, RS; Koopmans, PC; Ottervanger, JP; Sinagra, G; Ten Berg, JM; van 't Hof, AWJ | 1 |
| Cao, M; Cheng, L; Li, W; Li, Y; Pang, Z; Yao, Z | 1 |
| Aparci, M; Balta, S; Celik, T; Demir, M; Demirkol, S; Iyisoy, A; Kaya, MG; Kilic, S; Ozturk, C; Unlu, M; Yildirim, OA | 1 |
| Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Yang, XC; Zhang, DP | 1 |
| Dai, SP; Geng, T; Luo, Y; Song, ZY; Xu, ZS; Zhang, JG | 1 |
| Borklu, EB; Cinier, G; Eren, M; Hayiroglu, MI; Kaya, A; Keskin, M; Tatlisu, MA; Uzman, O | 1 |
| Cao, Z; Gao, L; Zhang, H | 1 |
| Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X | 1 |
1 review(s) available for tirofiban and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis.
Topics: Abciximab; Drug Therapy, Combination; Eptifibatide; Global Health; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Survival Rate; Tirofiban | 2019 |
13 trial(s) available for tirofiban and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Comparison of intracoronary versus intravenous tirofiban in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Anterior Wall Myocardial Infarction; Arrhythmias, Cardiac; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2022 |
Effect of intracoronary tirofiban following aspiration thrombectomy on infarct size, in patients with large anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adult; Anterior Wall Myocardial Infarction; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Injections, Intra-Arterial; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Thrombectomy; Tirofiban; Treatment Outcome | 2020 |
Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study.
Topics: Administration, Intravenous; Adult; China; Coronary Circulation; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and
Topics: Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
Topics: Adult; Aged; Aged, 80 and over; Anterior Wall Myocardial Infarction; Biomarkers; Diabetes Mellitus; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Reperfusion; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Prospective Studies; Regression Analysis; ST Elevation Myocardial Infarction; Time-to-Treatment; Tirofiban; Young Adult | 2021 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Emergency Medical Services; Europe; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Survival Rate; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Young Adult | 2017 |
Myocardial reperfusion with tirofiban injection via aspiration catheter : Efficacy and safety in STEMI patients with large thrombus burden.
Topics: Angioplasty, Balloon, Coronary; Fibrinolytic Agents; Humans; Myocardial Reperfusion; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Thrombosis; Tirofiban; Treatment Outcome | 2020 |
Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention.
Topics: Aged; Biomarkers; Double-Blind Method; Drug Administration Schedule; Emergency Medical Services; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2019 |
[The effect and safety of tirofiban on acute ST segment elevation myocardial infarction patients receiving no early reperfusion therapy].
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Safety; Secondary Prevention; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Aspiration thrombectomy and intracoronary tirofiban in ST-segment elevation myocardial infarction : Combination treatment for patients undergoing primary percutaneous coronary intervention.
Topics: China; Combined Modality Therapy; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prevalence; Risk Factors; ST Elevation Myocardial Infarction; Survival Rate; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Efficacy and Safety of Thrombectomy Combined with Intracoronary Administration of Tirofiban in ST-segment Elevation Myocardial Infarction (STEMI).
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Combined Modality Therapy; Coronary Angiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombectomy; Thrombosis; Tirofiban; Tyrosine | 2016 |
Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Cardiac Catheterization; China; Emergencies; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Radial Artery; Recombinant Proteins; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Warfarin; Young Adult | 2017 |
18 other study(ies) available for tirofiban and ST Elevation Myocardial Infarction
| Article | Year |
|---|---|
Correlation between culprit vessel/tirofiban and reperfusion bradyarrhythmia in patients with ST-segment elevation myocardial infarction after emergency PCI.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Bradycardia; Coronary Vessels; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
Topics: Aged; China; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2021 |
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Ticagrelor and tirofiban in pregnancy and delivery: beyond labels.
Topics: Adult; Cesarean Section; Female; Humans; Live Birth; Pregnancy; Pregnancy Complications, Cardiovascular; ST Elevation Myocardial Infarction; Ticagrelor; Tirofiban | 2020 |
Life after abciximab; what's next for intracoronary thrombus?
Topics: Abciximab; Aged; Aspirin; Coronary Thrombosis; Heparin; Humans; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2020 |
Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention.
Topics: Aged; Chi-Square Distribution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke Volume; Tirofiban; Treatment Outcome | 2020 |
Modulators of Mortality Benefit From Peri-Angioplasty Adjunctive Tirofiban in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Angioplasty, Balloon, Coronary; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Tirofiban; Treatment Outcome | 2021 |
Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention.
Topics: Abciximab; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial".
Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban | 2021 |
Thrombus resolution with tirofiban in the conservative management of patients presenting with plaque erosion.
Topics: Acute Coronary Syndrome; Adult; Aged; Cardiac Catheterization; Conservative Treatment; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tirofiban; Tomography, Optical Coherence | 2018 |
Effect of intra-coronary administration of tirofiban through aspiration catheter on patients over 60 years with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon, Coronary; Catheters; Drug Administration Routes; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2018 |
Acute Myocardial Infarction in Nephrotic Syndrome.
Topics: Adult; Anterior Wall Myocardial Infarction; Coronary Angiography; Coronary Vessels; Fibrinolytic Agents; Humans; Hypertension; Injections, Intra-Arterial; Male; Nephrotic Syndrome; Nitroglycerin; ST Elevation Myocardial Infarction; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine; Vasodilator Agents | 2015 |
Safety and efficacy of Tirofiban in STEMI-patients.
Topics: Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Germany; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Effects of Bailout Tirofiban on In-Hospital Outcomes and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
Topics: Adult; Aged; Cerebrovascular Disorders; Coronary Thrombosis; Female; Hospital Mortality; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Comparison of the effect of recombinant human pro-urokinase and tirofiban on myocardial blood flow perfusion in ST elevation myocardial infarction patients receiving primary percutaneous coronary intervention: A one-center retrospective observational stud
Topics: Aged; Coronary Circulation; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; ST Elevation Myocardial Infarction; Tirofiban; Urokinase-Type Plasminogen Activator; Ventricular Function, Left | 2019 |
Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adult; Age Factors; Chi-Square Distribution; Coronary Circulation; Female; Humans; Logistic Models; Lymphocyte Count; Male; Mean Platelet Volume; Middle Aged; No-Reflow Phenomenon; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Retrospective Studies; Risk Factors; Sex Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
Topics: Aged; Cause of Death; Coronary Thrombosis; Female; Hemorrhage; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |